Anabolic osteoporosis treatment
Romosozumab, abaloparatide and teriparatide for osteoporosis.
Key point
Abaloparatide has efficacy and safety similar to teriparatide and represents a new option for patients with severe osteoporosis and very high fracture risk.
From: Update of the SEIOMM clinical guideline of osteoporosis: abaloparatide (Rev Clin Esp (Barc), 2025 Oct) ↗Papers per year
Each bar is 12 months; the last one ends 17 Oct 2026. New trials in the same years: 0, 0, 0, 0, 0.
New guidelines and consensus this year
- Treatment of male osteoporosis: a narrative review and position statement by the ECTS Clinical Action GroupJ Bone Miner Res2026 Oct 6
- Pregnancy- and lactation-associated osteoporosis: A position statement of the IAPM, IOF, ECTS, ESCEO, IMS, and EMASInt J Gynaecol Obstet2026 Jul 16
- Follow-Up Care after Adult Lung Transplantation: Summary of an Evidence-Based Clinical Practice Guideline for German-Speaking CountriesRespiration2026 Jun 16
All papers from the last 12 months
345 papers (18 Oct 2025 – 17 Oct 2026), newest first. Loading the full list…
- Local strontium release from titanium implants and systemic sclerostin antibody synergistically improve biomechanical fixation and peri-implant bone quality in ovariectomized ratsBiomater Adv2026 NovPMID 42470817
- Managing Rebound Bone Loss After Denosumab Discontinuation: Mechanisms, Risk Stratification, and Sequential TherapyDrug Des Devel Ther2026PMID 42877773Review
- Predictors of the response to romosozumab in women with postmenopausal osteoporosis previously treated with denosumabBone2026 Oct 9PMID 42855028
- Treatment of male osteoporosis: a narrative review and position statement by the ECTS Clinical Action GroupJ Bone Miner Res2026 Oct 6PMID 42836541
- Effectiveness and Safety of Pharmacological Therapy for Osteoporosis in Frail Elderly Individuals: Systematic Review and Meta-AnalysisHealth Sci Rep2026 OctPMID 42835888Review
- Bone response to intermittent parathyroid hormone (PTH) is both genetic and sex specific in miceBone2026 Oct 3PMID 42829196
- Romosozumab Prescribing in Relation to Cardiovascular Disease History in Japan: A Nationwide Claims Database StudyCalcif Tissue Int2026 Oct 3PMID 42828587
- Denosumab-efficacy, safety, persistence and sequential strategies-a systematic reviewOsteoporos Int2026 Oct 2PMID 42825930Review
- Differential efficacy of initial versus sequential combination of denosumab and teriparatide in osteoporosis at high fracture riskOsteoporos Int2026 Oct 2PMID 42823542
- Conservative Treatment with Adjunctive Use of Teriparatide for Periprosthetic Humeral Fractures after Reverse Total Shoulder Arthroplasty: A Report of 6 CasesClin Orthop Surg2026 OctPMID 42876896
More endocrinology trends
All specialties →Menopausal hormone therapy
Hormone therapy for menopausal symptoms, benefits and risks.
Thyroid eye disease
Thyroid eye disease and targeted treatments such as teprotumumab.
Key point: IGF-1R inhibitors outperformed placebo across multiple thyroid eye disease efficacy outcomes, particularly in active disease, but increased adverse-event risk warrants vigilant monitoring.
CGM in type 2 diabetes
Continuous glucose monitoring for people with type 2 diabetes.
Key point: CGM is strongly recommended for people with type 2 diabetes treated with insulin and those not treated with insulin, particularly when HbA1c is ≥7%.
Cell therapy for type 1 diabetes
Islet transplantation and stem cell-derived beta cells.
Delaying type 1 diabetes
Teplizumab and other immunotherapy to delay type 1 diabetes.
Once-weekly insulin
Basal insulins given once a week, such as insulin icodec.
Key point: No clinically relevant differences were observed in hypoglycemic event duration or characteristics between once-weekly efsitora and once-daily basal insulin groups.
Too many papers to read?
PubDaily picks the ones that matter in your specialty and summarises them, about 10 minutes a week.
How these numbers are counted
PubMed query, searched in titles and abstracts by publication date:
(romosozumab[tiab] OR abaloparatide[tiab] OR teriparatide[tiab]) AND osteopor*[tiab]Trials: ClinicalTrials.gov studies first submitted in each 12-month window that match the same terms. A query can miss synonyms or catch unrelated papers, so treat counts as approximate.